Anti-VEGF DNA-based aptamers in cancer therapeutics and diagnostics(93 views) Riccardi C, Napolitano E, Platella C, Musumeci D, Melone MAB, Montesarchio D
Med Res Rev (ISSN: 0198-6325linking, 1098-1128electronic), 2021 Jan; 41(1): 464-506.
Department of Chemical Sciences, University of Naples Federico II, Naples, Italy.
Department of Advanced Medical and Surgical Sciences, 2nd Division of Neurology, Center for Rare Diseases and Inter-University Center for Research in Neurosciences, University of Campania Luigi Vanvitelli, Naples, Italy.
Institute of Biostructures and Bioimages, Naples, Italy.
Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, Pennsylvania, USA.
References: Not available.
Anti-VEGF DNA-based aptamers in cancer therapeutics and diagnostics
The vascular endothelial growth factor (VEGF) family and its receptors play fundamental roles not only in physiological but also in pathological angiogenesis, characteristic of cancer progression. Aiming at finding putative treatments for several malignancies, various small molecules, antibodies, or protein-based drugs have been evaluated in vitro and in vivo as VEGF inhibitors, providing efficient agents approved for clinical use. Due to the high clinical importance of VEGF, also a great number of anti-VEGF nucleic acid-based aptamers-that is, oligonucleotides able to bind with high affinity and specificity a selected biological target-have been developed as promising agents in anticancer strategies. Notable research efforts have been made in optimization processes of the identified aptamers, searching for increased target affinity and/or bioactivity by exploring structural analogues of the lead compounds. This review is focused on recent studies devoted to the development of DNA-based aptamers designed to target VEGF. Their therapeutic potential as well as their significance in the construction of highly selective biosensors is here discussed.
Anti-VEGF DNA-based aptamers in cancer therapeutics and diagnostics
Grünewald TG, Alonso M, Avnet S, Banito A, Burdach S, Cidre-aranaz F, Di Pompo G, Distel M, Dorado-garcia H, Garcia-castro J, González-gonzález L, Grigoriadis AE, Kasan M, Koelsche C, Krumbholz M, Lecanda F, Lemma S, Longo DL, Madrigal-esquivel C, Morales-molina Á, Musa J, Ohmura S, Ory B, Pereira-silva M, Perut F, Rodriguez R, Seeling C, Al Shaaili N, Shaabani S, Shiavone K, Sinha S, Tomazou EM, Trautmann M, Vela M, Versleijen-jonkers YM, Visgauss J, Zalacain M, Schober SJ, Lissat A, English WR, Baldini N, Heymann D * Sarcoma treatment in the era of molecular medicine(112 views) Embo Mol Med (ISSN: 1757-4676linking), 2020 Oct 13; 12(11): e11131-N/D. Impact Factor:10.293 ViewExport to BibTeXExport to EndNote